Search
rozanolixizumab-noli (Rystiggo)
Indication:
- generalized myasthenia gravis in adults who are anti-acetylcholine receptor or anti-muscle-specific tyrosine kinase antibody positive
Contraindications:
- chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) [2]
Dosage:
- subcutaneous infusion
Mechanism of action:
- neonatal Fc receptor inhibitor [2]
Interactions
drug adverse effects of pharmaceutical monoclonal antibodies
General
pharmaceutical monoclonal antibody
neurologic agent
References
- American Medical Association (AMA)
AMA Morning Rounds. June 28, 2023
- Querol L, De Seze J, Dysgaard T et al
Efficacy, safety and tolerability of rozanolixizumab in patients with chronic
inflammatory demyelinating polyradiculoneuropathy: a randomised, subject-blind,
investigator-blind, placebo-controlled, phase 2a trial and open-label extension
study.
J Neurol Neurosurg Psychiatry. 2024 May 10
PMID: 38729747 Free article.
https://jnnp.bmj.com/content/early/2024/05/10/jnnp-2023-333112.long